BIOMARIN PHARMACEUTICAL INC

Form 4

February 26, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per response...

OMB APPROVAL

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

Common

Common

Common

Common

Stock

Stock

Stock

Stock

(Print or Type Responses)

1. Name and Address of Reporting Person * **BIENAIME JEAN JACQUES**

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

BIOMARIN PHARMACEUTICAL INC [BMRN]

(Check all applicable)

Chief Executive Officer

(First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year) 02/24/2016

10% Owner _X_ Director X_ Officer (give title Other (specify below)

C/O BIOMARIN PHARMACEUTICAL INC., 770

(Street)

(State)

 $02/24/2016^{(1)}$

02/24/2016(1)

02/24/2016(1)

LINDARO ST.

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

SAN RAFAEL, CA 94901

1.Title of 3. 2. Transaction Date 2A. Deemed 4. Securities Acquired Transaction(A) or Disposed of (D) Security (Month/Day/Year) Execution Date, if (Instr. 3) Code (Instr. 3, 4 and 5) (Month/Day/Year) (Instr. 8) Code V Amount

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 5. Amount of 7. Nature of Indirect

Securities Ownership Beneficially Form: Direct Beneficial Owned (D) or Ownership Following Indirect (I) (Instr. 4) Reported (Instr. 4)

T

25,758

(A) Transaction(s) or (Instr. 3 and 4) (D) Price 94,850 \$0

A 323,104 D Α (4) (2)(3)\$0 198,400 A 521.504 D A

(4) (3)(5)\$0

21,978 D A 543,482 Α (6)(7)

> Shares held by

Bienaime

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Family Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exer	cisable and	7. Titl	e and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orNumber	Expiration D	ate	Amou	int of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	Secur
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	e		Securi	ities	(Instr. 5)	Bene
	Derivative				Securities	3		(Instr.	3 and 4)		Own
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
									or		
						Date	Expiration	Title	Number		
						Exercisable	Date		of		
				Code V	(A) (D)				Shares		

Dalationshin

Reporting Owners

Reporting Owner Name / Address	Keiationsnips					
ı		10% Owner	Officer	Other		
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901	X		Chief Executive Officer			

Signatures

/s/ Laura Randall Woodhead, Attorney-in-Fact 02/26/2016

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
- (2) Represents (A) the total number of RSUs earned for satisfaction of one of the performance conditions (approval of Vimizin in the U.S. or EU prior to December 31, 2015) set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share

Reporting Owners 2

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Incentive Plan, using the final Total Shareholder Return (TSR) as of December 31, 2015, less (B) the number of RSUs previously reported on Form 4 on February 19, 2014 as earned for satisfaction of the same performance condition determined using a lower, estimated TSR.

- Although earned, the RSUs only vest on the date of filing of the Issuer's Form 10-K for the fiscal year ended December 31, 2015, so long (3) as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events.
- (4) Price is not applicable to the RSUs.
- Represents the total number of RSUs earned for satisfaction of one of the performance conditions (Issuers's total revenue for the calendar year 2015, as certified by the Issuer's audited financials, equals or exceeds \$775 million) set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan using the final TSR as of December 31, 2015.
- Represents the total number of RSUs earned pursuant to a calculation based on the level of the Issuer's total adjusted revenues for the (6) fiscal year ended December 31, 2015, as certified by its audited financials, set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan.
- Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 3, 2016, 2017 and 2018, so long as (7) the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.